A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2ep53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours

被引：0
|
作者：
Schoeffski, P. [1 ]
Lorusso, P. [2 ]
Yamamoto, N. [3 ]
Lugowska, I. [4 ]
Garcia, V. Moreno [5 ]
Lauer, U. [6 ,7 ]
Hu, C. [8 ]
Jayadeva, G. [9 ]
Lahmar, M. [10 ]
Gounder, M. [11 ]
机构：
[1] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium
[2] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA
[3] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[4] Maria Sklodowska Curie Natl Res Inst Oncol, Early Phase Clin Trials Unit, Warsaw, Poland
[5] Hosp Fdn Jimenez Diaz, START Madrid, Madrid, Spain
[6] Univ Hosp Tubingen, Dept Med Oncol&Pneumol, Tubingen, Germany
[7] Univ Hosp Tubingen, Tubingen Early Phase Clin Trials Unit, Tubingen, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, Global Biostat&Data Sci, Ridgefield, CT USA
[9] Boehringer Ingelheim Pharmaceut Inc, TA Oncol Med, Ridgefield, CT USA
[10] Boehringer Ingelheim Int GmbH, TA Oncol Med, Ingelheim, Germany
[11] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1859
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
673P
引用
收藏
页码：S472 / S473
页数：2
相关论文
共 50 条
  • [1] A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumours
    Schoeffski, P.
    Yamamoto, N.
    Bauer, T.
    Patel, M.
    Gounder, M. M.
    Geng, J.
    Sailer, R.
    Jayadeva, G.
    Lorusso, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S743 - S743
  • [2] A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.
    LoRusso, Patricia
    Gounder, Mrinal M.
    Patel, Manish R.
    Yamamoto, Noboru
    Bauer, Todd Michael
    Laurie, Scott
    Grempler, Rolf
    Davenport, Teffany
    Geng, Junxian
    Rohrbacher, Maren
    Lahmar, Mehdi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
    LoRusso, Patricia
    Gounder, Mrinal M.
    Yamamoto, Noboru
    Patel, Manish R.
    Bauer, Todd Michael
    Geng, Junxian
    Sailer, Reinhard
    Tang, Yuefen
    Jayadeva, Girish
    Schoffski, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Efficacy and safety of brigimadlin (BI 907828), an MDM2-p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials
    Macarulla, Teresa
    Yamamoto, Noboru
    Tolcher, Anthony W.
    Hafez, Navid
    Lugowska, Iwona
    Ramlau, Rodryg
    Geng, Junxian
    Li, Jian
    Teufel, Michael
    Maerten, Angela
    Lorusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 487 - 487
  • [5] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma
    Gounder, M.
    Patel, M. R.
    Yamamoto, N.
    Bauer, T. M.
    Laurie, S.
    Perez-Pitarch, A.
    Geng, J.
    Cheng, J.
    Lahmar, M.
    Lorusso, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1124 - S1125
  • [6] The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
    LoRusso, Patricia
    Yamamoto, Noboru
    Patel, Manish R.
    Laurie, Scott A.
    Bauer, Todd M.
    Geng, Junxian
    Davenport, Teffany
    Teufel, Michael
    Li, Jian
    Lahmar, Mehdi
    Gounder, Mrinal M.
    CANCER DISCOVERY, 2023, 13 (08) : 1802 - 1813
  • [7] A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)
    Gounder, Mrinal M.
    Yamamoto, Noboru
    Patel, Manish R.
    Bauer, Todd Michael
    Schoffski, Patrick
    Grempler, Rolf
    Durland-Busbice, Sara
    Geng, Junxian
    Maerten, Angela
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Efficacy and safety of the MDM2-p53 antagonist BI 907828 in patients with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials.
    Yamamoto, Noboru
    Tolcher, Anthony W.
    Hafez, Navid
    Lugowska, Iwona
    Ramlau, Rodryg
    Gounder, Mrinal M.
    Geng, Junxian
    Li, Jian
    Teufel, Michael
    Maerten, Angela
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 543 - 543
  • [9] Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
    Yamamoto, Noboru
    Tolcher, Anthony
    Hafez, Navid
    Lugowska, Iwona
    Ramlau, Rodryg
    Macarulla, Teresa
    Geng, Junxian
    Li, Jian
    Teufel, Michael
    Maerten, Angela
    LoRusso, Patricia
    ONCOTARGETS AND THERAPY, 2024, 17 : 267 - 280
  • [10] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.
    Tolcher, Anthony W.
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony G.
    Lahmar, Mehdi
    Wang, Bushi
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345